PIK3CA and head and neck squamous cell carcinoma: Here, we investigated a new EGFR-based combination therapy using the natural compound deguelin, showing that the PIK3CA mutation is associated with sensitivity to EGFR TKIs, and that deguelin has a combination effect with an EGFR TKI for the induction of apoptosis in HNSCC cells.